Search Results

Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation.

• Authors : Luxun Tang; Qi Cai; Xiao Wang

Subjects: SODIUM-glucose cotransporters; PULMONARY arterial hypertension; SMOOTH muscle

• Source: Clinical & Experimental Hypertension. Dec2023, Vol. 45 Issue 1, p1-9. 9p.

Record details

Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis.

• Authors : GuangZhi Li; Dongmei Zhang; Jie Ni

Subjects: CANAGLIFLOZIN; DRUG efficacy; METFORMIN

• Source: Alternative Therapies in Health & Medicine. Oct2023, Vol. 29 Issue 7, p328-334. 7p.

Record details

Canagliflozin-induced Fanconi syndrome in a patient with previously unrecognized type 1 diabetes.

• Authors : Khan, Naseer; Tso, Katie; Broussard, Joan

Subjects: TYPE 2 diabetes diagnosis; ACIDOSIS; CLINICAL pathology

• Source: American Journal of Health-System Pharmacy. 12/1/2019, Vol. 76 Issue 23, p1930-1933. 4p. 2 Charts.

Record details

Canagliflozin or acarbose versus placebo to ameliorate post‐bariatric hypoglycaemia – The HypoBar I randomized clinical trial protocol.

• Authors : Lobato, Carolina B.; Winding, Clara Tornoe; Bojsen‐Møller, Kirstine N.

Subjects: PREVENTION of surgical complications; CANAGLIFLOZIN; BARIATRIC surgery

• Source: Diabetic Medicine. Jun2024, Vol. 41 Issue 6, p1-8. 8p.

Record details

The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance.

• Authors : VanDerStad, Lindsey R.; Wyatt, Emily C.; Vaughan, Roger A.

Subjects: CANAGLIFLOZIN; MITOCHONDRIA; SKELETAL muscle

• Source: Diabetic Medicine. May2024, Vol. 41 Issue 5, p1-9. 9p.

Record details

Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy‐arrhythmia burden in patients with cardiac implantable electronic devices.

• Authors : Younis, Arwa; Arous, Tania; Klempfner, Robert

Subjects: CAUSES of death; ELECTRODES; CONFIDENCE intervals

• Source: Journal of Cardiovascular Electrophysiology. Aug2023, Vol. 34 Issue 8, p1595-1604. 10p. 1 Diagram, 3 Charts, 3 Graphs.

Record details

Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.

• Authors : Ling Ding; Xi Chen; Wenxin Zhang

Subjects: CANAGLIFLOZIN; PROGRAMMED death-ligand 1; CYTOTOXIC T cells

• Source: Journal of Clinical Investigation. 1/3/2023, Vol. 133 Issue 1, p1-19. 19p.

Record details

Canagliflozin.

Subjects: DRUGS; TYPE 2 diabetes treatment; METFORMIN

• Source: Pulse. Oct2014 Supplement, p1-10. 10p.

Record details

Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.

• Authors : Nisly, Sarah A.; Kolanczyk, Denise M.; Walton, Alison M.

Subjects: HYPERGLYCEMIA prevention; CLINICAL trials; DIABETES

• Source: American Journal of Health-System Pharmacy. 2/15/2013, Vol. 70 Issue 4, p311-319. 9p. 1 Chart.

Record details

Retrospective review of SGLT2 inhibitor exposures reported to 13 poison centers.

• Authors : Schaeffer, Scott E. (AUTHOR); DesLauriers, Carol (AUTHOR); Spiller, Henry A. (AUTHOR)

Subjects: HYPOGLYCEMIC agents; TREATMENT of diabetes; DRUG toxicity

• Source: Clinical Toxicology (15563650). Mar2018, Vol. 56 Issue 3, p204-208. 5p.

Record details